Why the study?
Enterovirus virus-like particles normally require cleavage by potentially cytotoxic viral proteases like 3CD, prompting the need for protease-independent production methods.
Protease-independent production of enterovirus VLPs is feasible and yields stable, antigenic particles, potentially enabling novel mRNA or adenovirus-vectored vaccine approaches.
Answers are grounded in this paper and cite their sources.
Feasible protease-independent PV-1 VLP production with native properties; leaves open translation to human vectored vaccines.
The production of enterovirus virus-like particles (VLPs) which lack the viral genome have great potential as vaccines for a number of diseases, such as poliomyelitis and hand, foot-and-mouth disease. These VLPs can mimic empty capsids, which are antigenically indistinguishable from mature virions, produced naturally during viral infection. Both in infection and in vitro, capsids and VLPs are generated by the cleavage of the P1 precursor protein by a viral protease. Here, using a stabilised poliovirus 1 (PV-1) P1 sequence as an exemplar, we show the production of PV-1 VLPs in Pichia pastoris in the absence of the potentially cytotoxic protease, 3CD, instead using the porcine teschovirus 2A (P2A) peptide sequence to terminate translation between individual capsid proteins. We compare this to protease-dependent production of PV-1 VLPs. Analysis of all permutations of the order of the capsid protein sequences revealed that only VP3 could be tagged with P2A and maintain native antigenicity. Transmission electron microscopy of these VLPs reveals the classic picornaviral icosahedral structure. Furthermore, these particles were thermostable above 37°C, demonstrating their potential as next generation vaccine candidates for PV. Finally, we believe the demonstration that native antigenic VLPs can be produced using protease-independent methods opens the possibility for future enteroviral vaccines to take advantage of recent vaccine technological advances, such as adenovirus-vectored vaccines and mRNA vaccines, circumventing the potential problems of cytotoxicity associated with 3CD, allowing for the production of immunogenic enterovirus VLPs in vivo .
No takes yet. Share an insight, caveat, or question.
Sherry et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: